Core Insights - The behavior of margin traders has attracted significant market attention, with investors hoping to capture investment opportunities from their activities [1] Group 1: Margin Trading Data - On May 8, a total of 3,663 stocks received margin buying funds, with the top three stocks being Xinyi Technology (¥1.425 billion), Zhongji Xuchuang (¥1.053 billion), and Shenghong Technology (¥807 million) [1] - The table lists stocks with the highest margin buying amounts, including Tiancheng Technology (¥15.75 million), Xingqiu Graphite (¥8.83 million), and Lianyu Co. (¥15.27 million), showing their respective transaction amounts and margin buying ratios [1] - Margin buying accounted for significant percentages of total transaction amounts for various stocks, with Tiancheng Technology at 28.65%, Xingqiu Graphite at 28.51%, and Lianyu Co. at 28.15% [1] Group 2: Stock Performance - The price changes of stocks with high margin buying varied, with some stocks experiencing gains, such as Tiancheng Technology (1.47%) and Xingqiu Graphite (2.39%), while others like Fuliwang saw a decline (-3.29%) [1][2] - The data indicates that margin buying can correlate with stock performance, as seen in the fluctuations of the stocks listed [1][2]

Business Performance - In 2024, the company's main business segments generated a total revenue of CNY 2,273.76 million, accounting for 87.10% of total revenue, a decrease of 23.79% year-on-year [1] - The breakdown of revenue by segment is as follows: - Traditional Chinese Medicine (TCM): CNY 1,605.54 million (61.50%) - Chemical drugs: CNY 276.85 million (10.61%) - Chain pharmacy wholesale and retail: CNY 391.37 million (14.99%) - Health business: CNY 212.13 million (8.13%) [1] Product Development - The "Xuefu Zhuyu Oral Liquid" is a key product derived from a classic formula, recognized with multiple awards, including the National Science and Technology Progress Award [1] - In 2024, this product was selected for centralized procurement, which is expected to enhance its market share [2] Cost Control Measures - The company is addressing rising costs of herbal materials through several strategies: - Establishing GAP bases for stable supply of key herbs - Utilizing data analysis for demand forecasting and optimizing procurement [3] - Enhancing supply chain management and internal efficiency to reduce costs [3] Chemical Drug Segment - The chemical drug segment achieved a revenue of CNY 276.85 million in 2024, representing 10.61% of total revenue [4] - Key products include anti-tumor and immune-regulating drugs, with significant sales growth in specific items like injection RNA [4][6] - The company is focusing on deep market penetration and academic promotion to expand its market share [6] Retail and Wholesale Business - The chain pharmacy segment generated CNY 391.37 million in revenue, accounting for 14.99% of total revenue [8] - Membership increased by 18,300, totaling 1,189,000 members, with a net addition of 6 stores [8] - The company is enhancing online sales through major e-commerce platforms and implementing O2O strategies [9] Investment and Shareholder Returns - The company holds 20.05% of Guangfa Securities, its largest investment, enhancing its capital position [10] - A cash dividend of CNY 591 million is planned for 2024, reflecting a commitment to shareholder returns while balancing operational needs [12][13]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 √否 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000623 证券简称：吉林敖东 公告编号：2025-025 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况 □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 √不适用 公司不存在将《公开发行证券的公司信息披露解释性公告 ...

第十一届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码:000623 证券简称:吉林敖东 公告编号:2025-024 吉林敖东药业集团股份有限公司 一、董事会会议召开情况 1．吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会 第十七次会议通知以书面方式于2025年4月18日发出。 2．会议于2025年4月29日在公司六楼会议室以现场方式召开。 全文详见公司于2025年4月30日在《证券时报》《中国证券报》《上海证券 报》《证券日报》及巨潮资讯网http://www.cninfo.com.cn披露的《公司2025年 第一季度报告》（公告编号：2025-025）。 2．审议《关于聘任王超先生为公司副总经理的议案》 表决结果：通过。同意票9票，反对票0票，弃权票0票。 全文详见公司于2025年4月30日在《证券时报》《中国证券报》《上海证券报》 《证券日报》及巨潮资讯网http://www.cninfo.com.cn披露的《关于聘任公司副 3．本次会议应到会董事9名，实际参加会议现场表决董事9名。 4．会议由公司董 ...

吉林敖东：一季度归母净利润5.17亿元，同比增长259.75% 金十数据4月29日讯，吉林敖东公告，2025年第一季度实现营业收入6.23亿元，同比下降27.71%；归属 于上市公司股东的净利润5.17亿元，同比增长259.75%；基本每股收益0.4396元。 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥622,624,001.54, a decrease of 27.71% compared to ¥861,336,047.60 in the same period last year[4] - Net profit attributable to shareholders increased by 259.75% to ¥516,839,939.37 from ¥143,665,579.44 year-on-year[4] - Basic and diluted earnings per share rose by 244.24% to ¥0.4396 from ¥0.1277 in the same period last year[4] - Net profit for the current period is ¥516,513,643.37, compared to ¥132,653,063.68 in the previous period, representing a significant increase[19] - Earnings per share (EPS) for the current period is ¥0.4396, up from ¥0.1277 in the previous period[19] Cash Flow - The net cash flow from operating activities improved significantly, reaching ¥55,946,098.42, a 538.76% increase from -¥12,751,058.81 in the previous year[4] - Net cash flow from operating activities was $55,946,098.42, a significant improvement compared to a negative cash flow of $12,751,058.81 in the previous period[21] - Cash inflow from investment activities totaled $714,385,824.50, up from $125,583,727.14 in the prior period[21] - Net cash flow from investment activities was negative at -$57,839,340.16, compared to -$88,593,367.85 previously[21] - Cash inflow from financing activities amounted to $680,165,022.64, a decrease from $1,740,458,808.05 in the last period[22] - Net cash flow from financing activities was -$39,769,994.80, contrasting with a positive flow of $13,396,454.21 in the previous period[22] - The ending balance of cash and cash equivalents was $1,064,016,449.93, down from $1,631,979,783.39 at the end of the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥33,511,130,541.92, reflecting a 1.54% increase from ¥33,001,896,399.52 at the end of the previous year[4] - Total assets amount to ¥33,511,130,541.92, an increase from ¥33,001,896,399.52 in the previous period[17] - Total liabilities are ¥3,830,632,233.59, compared to ¥3,719,663,017.59 in the previous period, reflecting a rise[17] - The company’s goodwill and intangible assets are reported at ¥466,307,167.58, up from ¥437,315,884.41 in the previous period[16] Investment and Income - The company's investment income surged by 90.00% to ¥507,603,747.81 compared to ¥267,154,606.73 in the previous year[9] - The fair value change income was ¥7,289,911.33, a significant recovery from a loss of -¥202,651,117.19 in the same period last year, marking a 103.60% increase[9] Operating Costs and Expenses - The company reported a 37.78% reduction in operating costs, totaling ¥329,277,082.41 compared to ¥529,178,611.99 in the previous year[8] - Total operating costs for the current period are ¥622,063,638.81, down 25.4% from ¥834,140,687.01 in the previous period[18] - Research and development expenses decreased by 30.74% to ¥13,116,487.67 from ¥18,938,606.15 year-on-year[8] - Research and development expenses for the current period are ¥13,116,487.67, a decrease from ¥18,938,606.15 in the previous period[18] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 67,022[11] - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 27.35% of shares, totaling 327,080,749 shares[11] - The total number of preferred stock shareholders at the end of the reporting period is not applicable[13] Other Information - The company has not disclosed any new product or technology developments in this reporting period[14] - There are no significant mergers or acquisitions reported during this period[14] - The company has not provided specific future outlook or performance guidance in the current report[14]

证券代码:000623 证券简称:吉林敖东 公告编号: 2025-026 吉林敖东药业集团股份有限公司 关于聘任公司副总经理的公告 特此公告。 附件：王超先生简历。 吉林敖东药业集团股份有限公司董事会 2025 年 4 月 30 日 1 吉林敖东药业集团股份有限公司（下称"公司"）于 2025 年 4 月 29 日召开 第十一届董事会第十七次会议，审议通过了《关于聘任王超先生为公司副总经理 的议案》。结合市场环境、医药行业发展以及公司发展阶段，根据《公司法》《公 司章程》等相关规定，经总经理郭淑芹提名，公司董事会提名委员会审查，公司 董事会研究决定聘任王超先生担任公司副总经理，由王超先生负责公司整体医药 产品的战略统筹、渠道精耕、产销协同、品牌重塑等工作。任期自董事会会议审 议通过之日起至第十一届董事会任期届满为止。 王超先生不存在《公司法》《深圳证券交易所股票上市规则》等法律法规及 《公司章程》规定禁止任职的情形。公司董事会聘任王超先生为公司副总经理的 程序符合法律、法规和《公司章程》的有关规定。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 附件：王超先生 ...

证券代码：000623 证券简称：吉林敖东 吉林敖东药业集团股份有限公司 投资者关系活动记录表 编号：2025-002 | | □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 | | | --- | --- | --- | | 投资者关系活 | | | | 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称 | 通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 及人员姓名 | 参与本次 2024 年度业绩说明会的投资者 | | | 时间 | 2025 年 4 28 日（星期一）15:00—17:00 | 月 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待 | 副董事长、总经理：郭淑芹 | | | | 独立董事：肖维维 | | | 人员姓名 | 董事、副总经理、财务总监：张淑媛 | | | | 董事、副总经理、董事会秘书：王振宇 | | | | 1、行业以后 ...

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. reported a revenue of 2.611 billion yuan and a net profit of 1.551 billion yuan for 2024, with a debt-to-asset ratio of 11.27%, while actively adapting to changes in the pharmaceutical industry through a multi-driven development model of "pharmaceuticals + finance + health" [2][3] Group 1: Financial Performance - The company achieved a revenue of 2.611 billion yuan and a net profit attributable to shareholders of 1.551 billion yuan in 2024 [2] - The proposed cash dividend for 2024 is 3 yuan per 10 shares, totaling an estimated distribution of 352 million yuan, alongside a mid-year dividend of 239 million yuan, bringing the total cash dividends and share buybacks to 891 million yuan, which is 57.43% of the net profit [7] Group 2: Business Strategy - Jilin Aodong is focusing on building a competitive advantage across the entire pharmaceutical industry chain, including traditional Chinese medicine, chemical drugs, and health products, while enhancing its "pharmaceuticals + finance + health" multi-driven development model [3][4] - The company is implementing a marketing strategy centered on "big product groups + multiple product groups" to cultivate core products and strengthen channel management, aiming for a revenue of 2.274 billion yuan from its pharmaceutical segment [3][4] Group 3: Innovation and R&D - The company has established an innovative R&D system that integrates production, learning, and research, achieving significant results in the field of Chinese medicine formula granules [4][6] - Jilin Aodong is leveraging advanced research technologies and digital production to modernize and automate traditional Chinese medicine manufacturing, while also participating in the establishment of brand demonstration bases for Chinese medicinal materials [6][7]

Core Insights - The company reported a total revenue of 2.61 billion yuan in 2024, a decrease of 24.31% compared to 2023, which had a revenue of 3.45 billion yuan [1] - The pharmaceutical sector remains the main revenue driver, contributing 1.88 billion yuan, accounting for 72.11% of total revenue, despite a 27.83% decline from the previous year [1][3] - The company is focusing on key products in its traditional Chinese medicine segment, which includes core products like Anshen Bnna Liquid and Xiaor Chai Gui Oral Liquid, driving significant revenue [3] Revenue Breakdown by Sector - Pharmaceutical revenue: 1,882,395,047.83 yuan (72.11%), down 27.83% from 2,608,458,378.94 yuan [1] - Chain pharmacy wholesale and retail: 391,365,987.46 yuan (14.99%), up 4.36% from 375,020,113.62 yuan [1] - Other business income: 73,862,569.09 yuan (2.83%), up 62.06% from 45,577,260.70 yuan [1] Product Performance - Traditional Chinese medicine sales: 1,605,541,287.90 yuan (61.50%), down 25.42% from 2,152,662,657.59 yuan [1] - Chemical drugs revenue: 276,853,759.93 yuan (10.61%), down 39.26% from 455,795,721.35 yuan [1] - Health products sales reached 2.12 billion yuan, accounting for 8.13% of total revenue [4] Regional Performance - Northeast region: 968,305,996.09 yuan (37.09%), down 14.76% from 1,135,942,714.05 yuan [1] - North region: 377,546,862.16 yuan (14.46%), up 39.78% from 270,101,901.70 yuan [1] - South region: 330,176,089.26 yuan (12.65%), down 20.40% from 414,786,414.20 yuan [1] Sales Strategy and Growth - The company is enhancing its online sales through platforms like JD, Taobao, and Pinduoduo, while also implementing O2O business models in physical stores [4] - The chain pharmacy segment added 183,000 new members, bringing the total to 1.19 million members [3] - The company closed 11 stores and opened 17 new ones, ending the reporting period with a total of 190 stores [3]